NCT00306787

Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes

A Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Patient-initiated Famciclovir 1000 mg b.i.d. x 1 Day to Valacyclovir 500 mg b.i.d. x 3 Days in Immunocompetent Adults With Recurrent Genital Herpes

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,179 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the safety and efficacy of one-day famciclovir (1000 mg twice a day (b.i.d)) in reducing the duration of genital herpes lesions and the associated symptoms compared to three-day treatment with valacyclovir (500 mg capsule b.i.d).

Conditions

• Genital Herpes

Interventions

Type	Name	Description
DRUG	Famciclovir	Famciclovir 500 mg tablet
DRUG	Valacyclovir	Valacyclovir 500 mg capsule
DRUG	Placebo matching famciclovir	Famciclovir placebo, matching in size, color and forms of famciclovir tablet.
DRUG	Placebo matching valacyclovir	Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.

Timeline

• Start date: 2006-03-01
• Primary completion: 2008-02-01
• Completion: 2008-02-01
• First posted: 2006-03-24
• Last updated: 2011-06-30
• Results posted: 2011-06-17

Locations

66 sites across 4 countries: United States, Australia, Canada, Germany